Although constitutive expression of PD-L1 in tumors is considered as the mechanism that is less likely to be responsive to anti-PD-1/PD-L1 therapy despite their strong and diffuse PD-L1 expression pattern [40], limited numbers of studies in Hodgkin's lymphoma demonstrated a positive correlation between PD-L1 expression in tumors lacking PD-L1 positive T cells and their response to anti-PD-1/PD-L1 therapy [41]. The gene discussed is CD274; the disease is Hodgkins lymphoma.